<DOC>
	<DOCNO>NCT00323947</DOCNO>
	<brief_summary>This study evaluate safety effectiveness extend release methylphenidate ( XR-MPH ) treat attention deficit hyperactivity disorder ( ADHD ) child ADHD epilepsy .</brief_summary>
	<brief_title>Methylphenidate Treating Attention Deficit Hyperactivity Disorder Children With Both ADHD Epilepsy</brief_title>
	<detailed_description>Epilepsy brain disorder cluster nerve cell brain periodically send abnormal signal . The normal pattern nerve cell activity , therefore , becomes disrupt , result seizure . Some symptom epileptic seizure include follow : strange sensation , emotion , behavior ; convulsion ; muscle spasm ; loss consciousness . Children epilepsy risk specific disorder , ADHD , one common mental disorder child . ADHD characterize impulsiveness , hyperactivity , inattention . Approximately one third child epilepsy also ADHD . Stimulant medication common treatment method ADHD . The effect stimulant treatment epilepsy seizure frequency , however , unknown . This study evaluate safety effectiveness XR-MPH , stimulant medication , treat ADHD child ADHD epilepsy . People interested participate double-blind study first attend two visit interview evaluation determine eligibility participation . Upon study entry , participant randomly assign initially receive either XR-MPH placebo . Medication dosages duration study depend participant ' weight . Participants first take either immediate release MPH placebo `` A '' 1 day . Any participant experience adverse event remove study . On Day 2 treatment , participant assign receive XR-MPH begin take , participant assign receive placebo switch placebo `` B . '' This treatment phase continue 6 day 4 week , depend weight , follow 1-week medication washout period . Following washout , participant switch treatment group remainder study receive either XR-MPH placebo manner . Participants attend weekly study visit , receive medication undergo assessment ADHD symptom medication side effect . Blood drawn ass medication level first study visit follow round treatment . Participants trouble transportation study site may complete study visit via telephone . Upon study completion , participant offer clinical treatment study physician . Follow-up visit hold every 2 6 month patient choose continue receive care study physician .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Speaks English Intelligence Quotient ( IQ ) great 35 score great 35 Scales Independent Behavior Revised ( SIBR ) Broad Independence Scale ( IQ adaptive function Moderate Mental Retardation level high ) Diagnosis epilepsy International League Against Epilepsy ( ILEA ) criteria 26 ( repeat , afebrile , unprovoked seizure seizure within past 5 year ) Diagnostic Statistical Manual ( DSM ) IV diagnosis ADHD Scores least 4 CGI severity scale ADHD Scores great 90 % ADHD Rating Scale ( ADHD RS ) , Parent Version ; investigator score age sex either inattentive , hyperactiveimpulsive , total score first visit Has take stimulant alphaadrenergic medication 2 week prior study entry If take antidepressant , neuroleptic , lithium , dose stable 4 week Currently antiepileptic drug ( AED ) regimen stable dos 4 week prior study entry Seizurefree 1 month prior study entry Prescribing clinician epilepsy anticipates need stable AED regimen duration study Guardian give permission study personnel communicate prescribe epilepsy clinician Teacher agree fill ADHD RS baseline end arm study Has seizure within month precede study entry Change AED regimen dose within 4 week study entry History moderate severe adverse event relate MPH History psychotic disorder Current acute major depression bipolar mania Current psychiatric disorder require pharmacotherapy ( ADHD ) Unstable significant medical condition epilepsy Any known condition may make treatment MPH medically inadvisable Not currently work physician epilepsy treatment Previously participate trial provide adequate treatment XRMPH Weighs less 9 kg Pregnant Unwilling use effective form contraception Child take stimulant ( MPH , amphetamine preparation , pemoline ) , alphaadrenergic ( clonidine guanfacine ) , ADHD medication within 2 week screen telephone interview . Children withdrawn psychotropic medication order enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Seizures</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>Stimulant</keyword>
</DOC>